A single arm, prospective multicenter phase II study FOLFIRINOX in patients with advanced and recurrent biliary tract cancer.

被引：3
|
作者：
Takahara, Naminatsu
Isayama, Hiroyuki
Nakai, Yousuke
Ioka, Tatsuya
Kanai, Masashi
Sasaki, Takashi
Furuse, Junji
Koike, Kazuhiko
机构：
[1] Univ Tokyo, Tokyo, Japan
[2] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Tokyo, Japan
[3] Osaka Med Ctr Canc & Cardiovasc Dis, Hepatobiliary & Pancreat Oncol, Osaka, Japan
[4] Kyoto Univ Hosp, Kyoto, Japan
[5] JFCR, Canc Inst Hosp, Tokyo, Japan
[6] Kyorin Univ, Sch Med, Dept Med Oncol, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.TPS514
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS514
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A pilot phase II study of capecitabine in advanced or recurrent breast cancer.
    Saeki T.
    Kimura T.
    Toi M.
    Taguchi T.
    Breast Cancer, 2006, 13 (1) : 49 - 57
  • [42] Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial
    Zhu, Jun
    Song, Chunyan
    Zheng, Zhong
    Xia, Lingfang
    Chen, Yanqiong
    Ke, Guihao
    Wu, Xiaohua
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [43] Postoperative adjuvant tislelizumab plus lenvatinib and capecitabine for biliary tract cancer: Interim results of a prospective, single-arm, phase II study
    Feng, Y.
    Zhang, N.
    Zhao, Y.
    Pan, Q.
    Mao, A.
    Zhu, W.
    Lin, Z.
    Wang, L.
    Wang, Y. L.
    Zhou, J.
    Zhang, T.
    Wang, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S119 - S119
  • [44] A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer
    Liu, Ting
    Li, Qing
    Lin, Zhen
    Liu, Chunhua
    Pu, Wei
    Zeng, Shasha
    Lai, Jun
    Cai, Xuebin
    Zhang, Lisha
    Wang, Shuyang
    Chen, Miao
    Cao, Wei
    Gou, Hongfeng
    Zhu, Qing
    CANCER RESEARCH AND TREATMENT, 2024, 56 (02): : 602 - 615
  • [45] S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study
    Junji Furuse
    Takuji Okusaka
    Narikazu Boku
    Shinichi Ohkawa
    Akira Sawaki
    Toshikazu Masumoto
    Akihiro Funakoshi
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 849 - 855
  • [46] S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study
    Furuse, Junji
    Okusaka, Takuji
    Boku, Narikazu
    Ohkawa, Shinichi
    Sawaki, Akira
    Masumoto, Toshikazu
    Funakoshi, Akihiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (05) : 849 - 855
  • [47] Multicenter phase II study of gemcitabine (GEM) plus S-1 in patients (pts) with advanced biliary tract cancer (BTC)
    Sasaki, T.
    Isayama, H.
    Nakai, Y.
    Ito, Y.
    Togawa, O.
    Yagioka, H.
    Kogure, H.
    Yasuda, I.
    Hasebe, O.
    Maetani, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer: A multicenter phase I/II study
    Mitachi Y.
    Sakata Y.
    Ohtsu A.
    Hyodo I.
    Katsu K.
    Sairenji M.
    Saitoh S.
    Suwa T.
    Sato T.
    Miyata Y.
    Gastric Cancer, 2002, 5 (3) : 160 - 167
  • [49] Phase II study of S-1 in patients with unresectable or recurrent biliary tract cancer (BTC)
    Boku, N.
    Okusaka, T.
    Furuse, J.
    Ohkawa, S.
    Yamao, K.
    Masumoto, T.
    Funakoshi, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 318 - 318
  • [50] A multicenter, open-label, phase I study of nivolumab alone or in combination with gemcitabine plus cisplatin in patients with unresectable or recurrent biliary tract cancer.
    Ikeda, Masafumi
    Ueno, Makoto
    Morizane, Chigusa
    Kobayashi, Satoshi
    Ohno, Izumi
    Kondo, Shunsuke
    Okano, Naohiro
    Kimura, Keisuke
    Asada, Suguru
    Namba, Yoshinobu
    Okusaka, Takuji
    Furuse, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345